ATRC

NEUTRALAnalyst

AtriCure, Inc.

2026-10-23

Price

$58.97

-0.56%

This is the 2026-10-23 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score4.2Watchlist

Signals4/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

AtriCure (ATRC) is demonstrating High-Conviction Price Discovery, shrugging off a CAUTION macro regime as healthcare acts as a relative haven against geopolitical headwinds and surging oil prices. The stock's pristine technical setup—highlighted by a Steady Climb and Perfect Stack—is fundamentally supported by a wave of recent analyst upgrades, including a significant price target boost to $68 by Citizens JMP. This bullish divergence from the broader market's VIX expansion indicates strong institutional absorption as buyers position ahead of the upcoming Q3 earnings report.

Fired Signals

STEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: ATRC is a market leader exhibiting strong relative strength (+1.5% vs SPY) and institutional backing, making it a compelling long candidate in a volatile macro environment.
Key Risk: Broader market de-risking from escalating US/Iran tensions and surging WTI crude could overpower single-stock momentum, dragging down the healthcare sector.
What to Watch: Monitor the critical $52.84 support level to manage downside risk, while anticipating the upcoming Q3 earnings print on November 3 for fundamental confirmation.

← Back to 2026-10-23 View Full ATRC History →Yahoo Finance &nearr;